<DOC>
	<DOCNO>NCT01461317</DOCNO>
	<brief_summary>This study open-label extension ( OLE ) trial evaluate safety tolerability etrolizumab participant moderate severe ulcerative colitis ( UC ) enrol Phase II Study ABS4986g ( NCT01336465 ) meet eligibility criterion entry OLE study .</brief_summary>
	<brief_title>Study Evaluate Long-term Safety Etrolizumab Participants With Moderate Severe Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>All participant ( placebo active ) previously enrol Phase II study ( ABS4986g ) fulfill follow criterion : Participants obtain clinical response Phase II study ( ABS4986g ) Week 10 ( end Phase II treatment phase ) may enter OLE trial time Week 10 include Week 28 Participants clinical response Phase II study ( ABS4986g ) Week 10 flare UC Week 10 Week 28 Males female reproductive potential must willing use highly effective method contraception , vaginal ring , intrauterine device , physical barrier , vasectomized partner ) study start minimum 4 month ( approximately 5 halflives ) Concomitant immunosuppressive therapy must taper within 6 week enrollment OLE study Participants must taper completely oral corticosteroid within 24 week enrollment OLE study Participants complete Week 10 Phase II study ( ABS4986g ) Pregnancy lactation Any new malignancy within past 6 month Any new ( since enrol Phase II study [ ABS4986g ] ) , significant , uncontrolled , co morbidity , neurological , cardiac , pulmonary , renal , hepatic , endocrine , gastrointestinal ( GI ) disorder Any new clinically significant sign symptom infection judge investigator Any abnormal laboratory value record last visit complete Phase II study ( ABS4986g )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>